New Peer-Reviewed Publication on Laboratory Study That Demonstrated Simparica Trio® Protected 3x More Dogs From Infection With a Resistant Heartworm Isolate Than NexGard® Plus1
Business Wire•06/10/2026•07:30 ET
0
Key Highlights
- ➤Simparica Trio protected 2/8 dogs from adult heartworms versus 6/8 for NexGard Plus
- ➤Simparica Trio delivered 99.5% efficacy versus 98.1% for NexGard Plus
- ➤Simparica Trio-treated dogs had significantly lower average heartworm counts (P = 0.0316)
- ➤Simparica Trio uses 24 µg/kg moxidectin versus NexGard Plus's 12 µg/kg minimum
- ➤No treatment-related adverse events occurred in any dog during the study
Expert Statements
Jessica Rodriguez, Therapeutic Area Lead for Companion Animal Parasiticides, Veterinary Medicine Research and Development at Zoetis
“Veterinarians in areas where ML-resistant heartworm is circulating need to know that not all moxidectin dosages are equal. This study demonstrated that fewer dogs administered six monthly dosages of Simparica Trio had microfilariae at the end of a challenge study than dogs administered 6 monthly dosages of NexGard Plus,”
Lindsay Starkey, Veterinary Parasitologist at Oklahoma State University’s College of Veterinary Medicine, and Board Member of the American Heartworm Society
“Heartworm disease is easier and safer to prevent than to treat. Differences in active ingredient, dosage, and formulation can affect efficacy and compliance, making strict, on-label dosing and consistent year-round administration essential.”
New Peer-Reviewed Publication on Laboratory Study That Demonstrated Simparica Trio(®) Protected 3x More Dogs From Infection With a Resistant Heartworm Isolate Than NexGard(®) Plus(1)
Findings highlight dose-dependent efficacy of moxidectin in preventing heartworm disease
Get started
Create a free account to read the full story.